Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly will attend the Goldman Sachs Healthcare Conference on June 9-10, 2021. Key executives, including Anne White and Jake Van Naarden, will host a virtual fireside chat on June 9 at 8:50 a.m. ET. The session will be accessible via a live audio webcast on Lilly's Investor website, with a replay available for approximately 90 days.
Lilly is committed to developing life-changing medicines and improving disease management worldwide. For more information, visit www.lilly.com.
Eli Lilly and Company (NYSE: LLY) presented findings on migraine care at the AHS 2021 meeting, revealing 45% of participants hesitated to seek treatment. Key insights from the OVERCOME study highlighted barriers to optimal care. Emgality showed greater adherence (51.2%) compared to oral preventive treatments (27.6%). A discrete choice experiment demonstrated patient preference for the Emgality auto-injector. Additionally, REYVOW 100 mg and 200 mg exhibited superior efficacy in pain relief compared to Nurtec and UBRELVY. These findings underscore the need for improved migraine care discussions.
Eli Lilly and Incyte presented data at the EULAR Congress indicating that OLUMIANT® (baricitinib) 4 mg significantly reduced pain and morning joint stiffness while enhancing physical function at 12 weeks in moderate to severe rheumatoid arthritis patients compared to HUMIRA® (adalimumab) and placebo. The analysis, based on the Phase 3 RA-BEAM study with 1,305 participants, highlighted improved patient-reported outcomes and consistent safety results. OLUMIANT is approved in over 75 countries for RA treatment and recently received approval in Japan for COVID-19 pneumonia.
Eli Lilly and Company (NYSE: LLY) is set to present new data from Phase 3 studies at the virtual EULAR Congress (June 2-5, 2021), demonstrating Taltz's long-term efficacy and safety in axial spondyloarthritis (axSpA). In the COAST-Y study, continuous Taltz treatment showed that 56.7% of patients achieved ASAS40 after two years. Additionally, 89.6% of patients experienced no bone damage progression. Taltz has treated over 175,000 patients globally, supporting its use for multiple inflammatory conditions.
Eli Lilly's Phase 2 SERENITY study revealed that mirikizumab significantly alleviates fatigue in patients suffering from moderately to severely active Crohn's disease. At 12 weeks, patients receiving mirikizumab showed marked improvements in FACIT-Fatigue scores compared to placebo. This positive effect was sustained over one year. The study underscores the significance of fatigue as a symptom that correlates with disease activity and quality of life. This data is being showcased at Digestive Disease Week (DDW) 2021, reaffirming the need for innovative treatments for inflammatory bowel diseases.
Eli Lilly's tirzepatide achieved significant A1C and body weight reductions in adults with type 2 diabetes at increased cardiovascular risk in the SURPASS-4 clinical trial. The highest dose showed an A1C reduction of 2.58% and a weight loss of 11.7 kg compared to insulin glargine, which had an A1C reduction of 1.44% and weight gain. The study met all primary and secondary endpoints, demonstrating the potential of tirzepatide as a treatment option. A regulatory submission is planned by the end of 2021.
New data from Eli Lilly's oncology portfolio will be showcased at the 2021 ASCO Annual Meeting from June 4-8, 2021. Key highlights include a subgroup analysis of Verzenio® (abemaciclib) from the Phase 3 monarchE trial focused on hormone receptor-positive breast cancer and a first look at clinical data for Lilly's oral selective estrogen receptor degrader. Additionally, updates on Retevmo® (selpercatinib) for lung and thyroid cancer will be presented, alongside findings related to CYRAMZA® and ERBITUX® in gastrointestinal cancers, emphasizing treatment outcomes and patient demographics.
Innovent Biologics and Eli Lilly announced that the U.S. FDA has accepted for review a Biologics License Application (BLA) for sintilimab injection combined with pemetrexed and platinum chemotherapy for first-line treatment of nonsquamous non-small cell lung cancer (NSCLC). This landmark application marks the first submission of sintilimab outside of China, following its regulatory approval in China earlier in 2021.
The FDA plans to decide by March 2022, with no review issues identified at this stage.
Eli Lilly will participate in the UBS Global Healthcare Virtual Conference on May 26, 2021, at 10:00 a.m. ET. Anat Ashkenazi, CFO, will engage in a virtual fireside chat during the event. A live audio webcast will be hosted on Lilly’s Investor website, with a replay available for 90 days. Founded over a century ago, Eli Lilly is dedicated to discovering and delivering innovative medicines globally. To learn more about the company, visit www.lilly.com.
Eli Lilly and Company (NYSE: LLY) has entered a global research collaboration with MiNA Therapeutics to explore novel drug candidates using MiNA's small activating RNA (saRNA) technology. MiNA will investigate up to five targets identified by Lilly, which will handle preclinical and clinical development, retaining exclusive commercialization rights. MiNA will receive a $25 million upfront payment and is eligible for additional milestones totaling $245 million per target. The collaboration is expected to enhance Lilly's RNA therapeutics portfolio without impacting its 2021 non-GAAP earnings per share guidance.